<DOC>
	<DOC>NCT01158898</DOC>
	<brief_summary>This is a randomized, double-blind, placebo-controlled, 3-way crossover trial to evaluate the efficacy and safety of two different doses of inhaled TPI ASM8 administered daily for 14 days for the treatment of allergic asthma and allergen-induced asthma.</brief_summary>
	<brief_title>Efficacy of TPI ASM8 During a 14-Day Allergen Challenge</brief_title>
	<detailed_description>Two doses of TPI ASM8 will be compared to placebo and look at the effect on asthmatic responses after an allergen challenge during a 3-way cross over design. Sputum inflammation , mRNA gene expression on target receptors, ECP , biomarkers of mast cells activation et PK profile will be studied.</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Mild asthma, male and female aged 1855 y.old Steroidnaive, nonsmoker Dual responders Any chronic disease(unstable) Immunosuppressed, recent or ongoing steroid intake Methacholine PC 20 &gt; 16 mg/mL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Mild to moderate asthma</keyword>
	<keyword>Allergen inhalation challenge</keyword>
</DOC>